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Background: There is a need to have uniformed reporting of perinatal mortality for births following assisted
reproductive technology (ART) treatment to enable international comparison and benchmarking of ART practice.
Methods: The Australian and New Zealand Assisted Reproduction Database was used in this study. Births of≥ 20 weeks
gestation and/or ≥ 400 grams of birth weight following embryos transfer cycles in Australia and New Zealand
during the period 2004 to 2008 were included. Differences in the mortality rates by different perinatal periods
from a gestational age cutoff of ≥ 20, ≥ 22, ≥ 24, or ≥ 28 weeks (wks) to a neonatal period cutoff of either < 7
or < 28 days after birth were assessed. Crude and specific (number of embryos transferred and plurality) rates of
perinatal mortality were calculated for selected gestational and neonatal periods.
Results: When the perinatal period is defined as ≥ 20 wks gestation to < 28 days after birth, the perinatal
mortality rate (PMR) was 16.1 per 1000 births (n = 630). A progressive contraction of the gestational age groups
resulted in marked reductions in the PMR for deaths at < 28 days (22 wks 11.0; 24 wks 7.7; 28 wks 5.6); and
similarly for deaths at < 7 days (20 wks 15.6, 22 wks 10.5; 24 wks 7.3; 28 wks 5.3). In contrast, a contraction of the
perinatal period from < 28 to < 7 days after birth only marginally reduced the PMR from 16.2 to 15.6 per 1000
births which was consistent across all gestational ages.
The PMR for single embryo transfer (SET) births (≥ 20 weeks gestation to < 7 days post-birth) was significantly
lower (12.8 per 1000 SET births) compared to double embryo transfer (DET) births (PMR 18.3 per 1000 DET births;
p < 0.001, Fisher’s Exact Test). Similarly, the PMR for SET births (≥ 22 weeks gestation to < 7 days post-birth) was
significantly lower (8.8 per 1000 SET births, p < 0.001, Fisher’s Exact Test) when compared to DET births (12.2 per
1000 DET births). The highest PMR (50.5 per 1000 SET births, 95% CI 36.5-64.5) was for twins following SET births
(≥ 20 weeks gestation to < 7 days post-birth) compared to twins following DET (23.9 per 1000 DET births, 95%
CI 20.8-27.1).
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Conclusion: Reporting of perinatal mortality of ART births is an essential component of quality ART practice. This
should include measures that monitor the impact on perinatal mortality of multiple embryo transfer. We
recommend that reporting of perinatal deaths following ART treatment, should be stratified for three gestation-
specific perinatal periods of ≥ 20, ≥ 22 and ≥ 28 completed weeks to < 7 days post-birth; and include plurality
specific rates by SET and DET. This would provide a valuable international evidence-base of PMR for use in
evaluating ART policy, practice and new research.
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mortalityBackground
There is international agreement of the importance of
perinatal mortality measures for monitoring pregnancy
and childbirth with routine reporting at a country and re-
gional level [1]. This monitoring does not commonly ex-
tend to births following assisted reproductive technology
(ART) treatment with only Australia and New Zealand,
Latin America, Japan and Canada including perinatal mor-
tality measures in their most recent ART reports [2-5].
In contrast, the ART reports from the United States
and Europe present data on the births of almost
150,000 babies but no information on mortality [6,7].
The lack of perinatal mortality data is a major health
information gap in benchmarking the quality of ART
policy and the safety of practice.
Internationally, monitoring and comparison of peri-
natal mortality is limited by the wide variation in the
definitions of birth, stillbirth and perinatal death used in
countries that practice ART (Table 1) [3,4,8,9]. The
World Health Organization (WHO) recommends for
international comparison that the definition of births be
restricted to 1000 grams and/or 28 weeks gestation for
all perinatal measures [10] but the usefulness of this def-
inition for monitoring perinatal mortality is limited for
births following ART where there are proportionately
high rates of multiple birth and preterm birth [11]. In
2009, the International Committee Monitoring Assisted
Reproductive Technologies (ICMART) and the WHO
sought to limit the perinatal period for birth following
ART treatment to ≥20 completed weeks of gestational
age to <7 completed days after birth regardless of birth
weight [12]. However, for many countries birth data are
not available for gestations of <22 weeks limiting the
utility of international comparison based on the
ICMART/WHO definition of birth.
Further, when agreeing on the perinatal measures to
monitor ART, the impact of ART treatment practices
needs to be considered, most notably the number of em-
bryos transferred. The literature show increased risk of
multiple gestation with the transfers of two or more em-
bryos [13]. For example in 2010, in Quebec, Canada, the
change in policy to elective single embryo transfer (SET)(from 1.6% of cycles to 50%) resulted in a reduction in
the multiple pregnancy rate from 25.6% in 2009 to 3.7%
in the first three months of implementation of a policy
of SET [14].
Reducing the number of embryos per transfer is essen-
tial to lower both perinatal morbidity and mortality for
ART births [13,15]. Among the risk factors for perinatal
mortality, iatrogenic multiple gestation pregnancy can be
considered the most significant preventable risk for
women undergoing ART treatment. Research studies
and subsequent policy implementation of SET in New
Zealand, Sweden, Belgium and Quebec have reduced the
proportion of double embryo transfers (DET) and mul-
tiple gestations but have not routinely reported embryo-
transfer specific perinatal mortality [13,16-18]. This lack
of reporting of embryo-transfer specific rates of perinatal
mortality limits evaluation of the policy of SET [19]. The
aim of this study is to develop an approach for
standardization of reporting of PMR following ART
treatment for international comparison. We applied
commonly used American and European perinatal pe-
riods to the Australian and New Zealand ART registry
data, to investigate the changes in PMRs stratified by
plurality and number of embryos transferred.
Methods
A review of reporting perinatal mortality of ART births
was conducted. The 2004-2008 data from the Australia
and New Zealand Assisted Reproductive Database
(ANZARD) were used to assess the differences in the
definitions of perinatal periods based on internationally
used gestational age at birth and number of days after
birth. ANZARD is a census of all initiated ART treat-
ment cycles undertaken in Australia and New Zealand.
Items on ANZARD are collated annually by the National
Perinatal Epidemiology and Statistics Unit (NPESU), in a
de-identified format, from all fertility centres within
Australia and New Zealand. Fertility centres as part of
their quality assurance are required to report ART treat-
ment and outcomes to ANZARD. Birth outcomes col-
lected in ANZARD include birth status, gestational age,
birth weight, date of neonatal death and congenital
Table 1 Definitions of perinatal mortality internationally













20 – < 7
Australia 20 400 < 28
Canada 20 – < 7
United States 20 350 < 28
Latin America 20 – < 28
Europe1 22 500 < 7
Europe2 22 – < 7
Europe3 22 1000 < 7
Japan 22 – < 7
World Health Organization
(WHO) (national reporting)
22 500 < 7




28 1000 < 7
Europe5 28 – < 7
1Includes Norway, France, Finland, Estonia, Belgium, Netherlands, Malta.
2Includes Spain (Valencia), Latvia, Lithuania, Denmark, Slovak Republic.
3Includes Czech Republic.
4Includes Ireland, Hungary, Portugal.
5Includes Sweden, Greece.
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ANZARD is audited for completeness and accuracy on
an annual basis as part of accreditation for fertility
clinics through the Reproductive Technology Accredit-
ation Committee.
Australian definition of birth and the perinatal period
The Australian definition of a birth is all live and stillbirths
(fetal deaths) of ≥20 weeks gestation and/or ≥400 grams
of birth weight. The perinatal period is defined for
liveborns to <28 complete days after birth. The study
population includes all births following ART treatments
that occurred during the period 1 January 2004-31
December 2008. A total of 50,258 ART births were used
to calculate the PMR according to different international
published definitions.
Comparison with international definition
The inclusion criteria for fetal deaths varied internation-
ally by gestation and or birthweight for both ART and
spontaneous births (Table 1). The gestational age low
limits for fetal death vary between countries, rangingfrom 16 to 28 weeks [20]. In Australia, New Zealand,
the United States, Canada and Latin America, a gesta-
tional age of ≥20 complete weeks is used to define a
birth [3,4,8,21-25]. In contrast, there is marked vari-
ability in the definition of birth among European coun-
tries. For some countries (e.g. Norway, France and
Finland) the inclusion criteria for a birth is a gesta-
tional age of ≥22 complete weeks [26-28], while for
others the gestational age is either ≥24 (United Kingdom)
[29] or ≥28 weeks (Sweden and Denmark) [28,30]. Else-
where, birthweight is used to define a birth [23,28,31]. In
other countries, birthweight is not one of the inclusion
criteria [3,4]. The definitions of neonatal period also vary
by countries and regions using either <7 completed days
[29] or <28 completed days after birth [24,25] (Table 1).
Definition of stillbirth, neonatal death and perinatal death
Perinatal mortality rates for ART births were abstracted
from published studies or reports. Studies/reports
needed to satisfy the following criteria to be included:
[1] data extracted from a national or regional ART regis-
try; [2] overlapping data for the time period of the study
(2004-2008); and [3] mortality measures with clear defi-
nitions. There were no published reports from the
United Kingdom on perinatal mortality so the statistics
were calculated using publicly available data [23,31]. The
perinatal periods were defined in various ways
dependent upon the country, region or international
organization (Table 1).
Table 2 details the definitions of fetal, neonatal and
perinatal mortality used in this study. Eight commonly
used definitions of perinatal periods (Tables 1, 2) were
examined to assess the differences in PMRs. To demon-
strate the importance of direct comparison of PMRs for
ART births using the same perinatal period, the defini-
tions of perinatal mortality which were published in
journal articles and national/regional reports of Canada,
the United Kingdom, Sweden, Japan, Finland, Norway
and Latin America were adopted to compute specific
PMRs for Australia and New Zealand.
Statistical analysis
The rates of fetal, neonatal and perinatal mortality were
expressed per 1000 births. Fetal and PMRs were calcu-
lated using all births (live births and fetal deaths) as the
denominator. Neonatal mortality rates were calculated
using live births as the denominator. According to the
literature, PMRs for the periods listed in Table 2 were
computed. The differences in PMRs at different gesta-
tional ages (20, 22, 24 and 28 weeks) and different num-
ber of days after birth (<7 or <28 days) were compared.
These were in accordance with the countries’ or organi-
zations’ PMR definitions. Plurality (singletons and twins)
and number of embryos transferred (single and double)
Table 2 Variations in the definitions of fetal, neonatal and perinatal death
Gestational age at birth dependent on country or organisation
definition (weeks)
Survival after birth (days)
≥ 20 ≥ 22 ≥ 24 ≥ 28 < 7 < 28
Fetal death Neonatal death
Death prior to complete expulsion or extraction from its mother of a product of
conception at a defined number of completed weeks of gestational age
Death that occurs of a liveborn infant in the neonatal period
defined as either <7 or <28 completed days after birth
Perinatal death
Any fetal and/or neonatal death that occurs within the defined perinatal period
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SET and DET births was tested by Fisher’s exact method.
Data were analyzed using SPSS, version 19.0 (SPSS Inc.,
Chicago, Ill, USA).
Ethics
Ethics approval for this study was granted by the Human
Research Ethics Advisory Panel of the University of New
South Wales, Australia (Reference 2010-7-55). Approval
for use of these data in research was received from the
Fertility Society of Australia and New Zealand.
Results
Rates of perinatal mortality for Australia and New
Zealand using different international perinatal period
scopes
Table 3 presents the rates of fetal, neonatal and perinatal
mortality following ART in Australia and New Zealand
by applying the four most common gestational age cri-
teria and either <7 and <28 completed days after a live
birth. The inclusion of earlier gestational ages resulted in
increased rates of fetal, neonatal, and perinatal mortality.
When the perinatal period was defined as ≥ 28 weeks’ ges-







To: days survived after
birth
Number Number
≥ 201 < 28 50252 625
≥ 22 < 28 49981 416
≥ 24 < 28 49760 289
≥ 28 < 28 49212 223
≥ 202 < 7 50252 625
≥ 22 < 7 49981 416
≥ 24 < 7 49760 289
≥ 283 < 7 49212 223
1Australian/New Zealand definition includes all live and stillbirths of ≥20 completed
neonate <28 complete days after birth.
2ICMART defines the perinatal period as births of ≥20 completed weeks of gestation
3WHO defines the perinatal period births of ≥28 completed weeks of gestation to <was 5.3 per 1000 births, this almost tripled to 16.1 per
1000 births when the (Australian definition) ≥ 20 weeks
gestational age to < 28 days after birth was applied. Over
64% of fetal deaths (n = 402) were excluded when using
the WHO definition as compared to the Australian defin-
ition. Similarly, almost 80% of neonatal deaths (n = 143)
were not counted when changing the scope of perinatal
period used in Australia to that used by WHO. The ma-
jority of neonatal deaths occurred < 7 days after birth, with
86% of neonatal deaths for babies born at a gestational
age ≥ 20 weeks being early neonatal deaths compared to
74% for gestational age ≥ 28 weeks.
Comparative international rates of perinatal related
mortality measures
Table 4 presents the computed PMRs for Australia and
New Zealand using the same scope and definition of other
countries and regions. The crude PMR was significantly
lower in Australia and New Zealand as compared to
Canada, the United Kingdom, Japan and Latin America.
In contrast, the singleton specific PMR was significantly
higher in Australia and New Zealand compared to
Sweden, Finland and Latin America but significantly lower
than in Japan. These crude rates have not been adjustedwing ART treatment by different international definitions







100.0 182 100.0 16.1
66.6 135 74.2 11.0
46.2 95 52.2 7.7
35.7 53 29.1 5.6
100.0 157 100.0 15.6
66.6 110 70.1 10.5
46.2 73 46.5 7.3
35.7 39 24.8 5.3
weeks of gestation and/or ≥400 grams of birthweight and death of a
to <7 completed days after birth regardless of birthweight.
7 completed days after birth regardless of birthweight.
Table 4 Comparison of international perinatal mortality definitions and rates as applied to Australia and New Zealand1









Published Computed Australia and
New Zealand1,2,3
P value
Canada, 2007 20 28 Singletons 12.6 12.4 0.93
Twins 31.8 27.4 0.28Gunby et al. 2011
HOM4 55.6 101.2 0.18
Overall 21.8 16.1 <0.01
United Kingdom, 1991-2010 24 28 Overall 17.8 7.7 <0.01
HFEA, 20115
Sweden, 2002-2006 28 7 Singletons 3.7 5.6 0.03
Sazonova et al. 2011
Japan, 2006 22 7 Singletons 16.3 8.3 <0.01
Fujii et al. 2010
Finland, 1995-2006 22 7 FET6 singletons 4.4 6.0 0.38
Pelkonen et al. 2010 Fresh singletons 5.4 6.4 0.52
Latin America, 1990-2009 20 28 Singletons 9.9 12.1 <0.01
Twins 27.8 26.2 0.41Zegers Hochschild et al. 2011
HOM4 77.5 98.2 0.16
Overall 23.7 15.6 <0.01
Norway, 1984-2006 22 7 Singletons 9.5 8.3 0.27
Romundstad et al. 2008
1Calculated from ANZARD data, 2004-2008.
2Calculated using the same time period for the years of data 2004–2008; if the data includes the 5 years of data plus additional data only 2004-2008 Australian
and New Zealand data used.
3Differences in the computed Australian and New Zealand rates reflect the different time periods.
4HOM higher order multiple excludes twins.
5Calculated from publically available HFEA data.
6FET frozen embryo transfer.
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and treatment factors but show the enormous variability
in perinatal mortality rates following ART treatment
across countries and regions.
Benchmarking of perinatal mortality after ART
Table 5 shows the perinatal mortality for births for two
perinatal periods stratified by the number of embryos
transferred and plurality. The PMR for SET births
(from ≥20 weeks gestation to <7 days after birth) was
significantly lower (12.8 per 1000 SET births) compared to
DET births (PMR 18.3 per 1000 DET births; p < 0.001,
Fisher’s Exact Test). Similarly, the PMR for SET births
(from ≥22 weeks gestation to <7 days after birth) was sig-
nificantly lower (8.8 per 1000 SET births, p < 0.001,
Fisher’s Exact Test) when compared to DET births (12.2
per 1000 DET births). Thirty-two percent of perinatal
deaths of singletons and twins were excluded when the
two week narrower perinatal period of ≥22 weeks gesta-
tion to <7 days after birth was used. The highest rate of
fetal mortality is for twins following SET, there was a non
significant fall in the fetal death rate when the narrower
perinatal period of ≥22 weeks gestation was used.Discussion
This study shows that the wide variation in the measures
used for reporting perinatal mortality at a country and
regional level limits direct comparison and evaluation of
ART policy and best practice internationally. Monitoring
of perinatal mortality is an essential component of any
quality system that seeks to improve ART services and
the related maternal and perinatal outcomes. Unlike nat-
ural conception, ART treatment involves elective deci-
sion making on the part of the clinician and couple,
most notably about the number of embryos transferred.
The number of embryos transferred is highly correlated
with the risk of multiple gestation pregnancies, which
remain prevalent in most countries [13,14]. Therefore, it
is essential that routine perinatal mortality measures fol-
lowing ART are able to monitor the impact of embryo
transfer practices among countries.
This study demonstrates the impact different defini-
tions of perinatal mortality have on PMRs. The PMR for
Australia and New Zealand was 16.1 per 1000 births
(Australian definition ≥ 20 weeks gestation to <28 days
post-birth) compared to 5.1 per 1000 births, when the more
limited WHO recommended definition for international




Number Mortality rate and (95% CI) /denominator
Total births Fetal deaths Neonatal deaths Fetal 1000 births Neonatal /live births Perinatal /1000 births
From ≥ 20 weeks gestational age to < 7 survival days after birth
Single embryo transfer
Singletons 24199 235 38 9.7(8.5-11.0) 1.6(1.1-2.1) 11.3(9.9-12.6)
Twins 990 41 9 41.4(28.7-54.1) 9.5(3.3-15.7) 50.5(36.5-64.5)
All births1 25220 277 47 11.0(9.7-12.3) 1.9(1.3-2.4) 12.8(11.4-14.2)
Double embryo transfer
Singletons 15115 172 29 11.4(9.7-13.1) 1.9(1.2-2.6) 13.3(11.5-15.1)
Twins 9150 151 68 16.5(13.9-19.1) 7.6(5.8-9.4) 23.9(20.8-27.1)
All births1 24525 343 106 14.0(12.5-15.5) 4.4(3.5-5.2) 18.3(16.6-20.0)
All transfers2
Singletons 39624 410 69 10.3(9.3-11.3) 1.8(1.3-2.2) 12.1(11.0-13.2)
Twins 10292 193 77 18.8(16.1-21.4) 7.6(5.9-9.3) 26.2(23.1-29.4)
All births1 50252 625 157 12.4(11.5-13.4) 3.2(2.7-3.7) 15.6(14.5-16.7)
From ≥ 22 weeks gestational age to < 7 survival days after birth
Single embryo transfer
Singletons 24200 159 28 6.6(5.5-7.6) 1.2(0.7-1.6) 7.7(6.6-8.8)
Twins 990 28 6 28.3(17.8-38.8) 6.2(1.2-11.2) 34.3(22.8-45.9)
All births1 25108 187 34 7.4(6.4-8.5) 1.4(0.9-1.8) 8.8(7.6-10.0)
Double embryo transfer
Singletons 15046 118 17 7.8(6.4-9.3) 1.1(0.6-1.7) 9.0(7.5-10.5)
Twins 9075 95 50 10.5(8.4-12.6) 5.6(4.0-7.1) 16.0(13.4-18.6)
All births1 24353 225 72 9.2(8.0-10.4) 3.0(2.3-3.7) 12.2(10.8-13.6)
All transfers2
Singletons 39461 279 47 7.1(6.2-7.9) 1.2(0.9-1.5) 8.3(7.4-9.2)
Twins 10199 124 56 12.2(10.0-14.3) 5.6(4.1-7.0) 17.6(15.1-20.2)
All births1 49981 416 110 8.3(7.5-9.1) 2.2(1.8-2.6) 10.5(9.6-11.4)
1include higher order multiples.
2include transfers of three or more embryos.
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birth) was applied [10,23]. Application of the WHO
definition results in the exclusion of 1,040 (9.5%) pre-
term births, 402 (64.3%) stillbirths and 143 (78.6%)
neonatal deaths. These differences can be overcome by pre-
senting data for three gestational time periods (≥ 20
weeks, ≥ 22 weeks, ≥ 28 weeks and limiting the peri-
natal period to 7 days post birth) where the majority of
neonatal deaths occur. This would allow international
comparison. The first of these proposed definitions
would be consistent with ICMART / WHO glossary def-
inition of a perinatal death and could be adopted as a
standard for international reporting [12]. The inclusion
of ≥20 completed weeks’ gestation would allow greater
utility to investigate the impact of ART and multiple gesta-
tion from the provision of neonatal services.Most countries follow the WHO definition (gestational
age of 22 weeks or birth weight of 500 grams and <7 days)
for national reporting of perinatal mortality. However,
some countries only use gestational age and others birth
weight [30]. Birth weight is included in the definition of
perinatal mortality, particularly in low income countries,
as it is easier to measure and less prone to error than cal-
culations of gestational age from the last menstrual period
[32]. In contrast, Mohangoo et al. suggested that mortality
rates are usually underestimated if the case definition in-
cludes birth weight rather than gestational age. This was
demonstrated in the Euro-Peristat project which reported
comparatively lower fetal death rates when birth weight
criteria was used rather than gestational age [33]. There-
fore, most of the high income countries prefer to use ges-
tational age, given it is more sensitive predictor for the
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births following ART treatment are calculated based on
date of embryo transfer and date of delivery which are
usually collected in ART registers [34,35]. Regardless of
which criteria are used, the variation in birth registration
practices and in scope of perinatal periods significantly
changes the international rankings of countries based on
mortality rates [36]. Standardization in perinatal data
collection and reporting will help in monitoring ART
treatment practices and is consistent with the recommen-
dations from the Global report on preterm birth and still-
birth [20].
The clinical relevance of benchmarking of ART prac-
tice with the reporting of embryo-specific- and
plurality-specific-rates of perinatal mortality is evident.
The transfer of two or more embryos significantly in-
creases the risk of multiple gestation pregnancy [13,37].
Multiple gestation pregnancies are at higher risk of
fetal, neonatal and perinatal mortality than singleton
pregnancies [15]. In this study, SET was associated with
a significantly lower PMR for all births when compared
to DET. Double embryo transfers were associated with
one extra death per 200 births. In contrast, twin gesta-
tions following SET resulted in a significantly higher
PMR compared to DET.
Further, there is wide variation in the number of em-
bryos transferred by countries and regions and the policy
framework for SET [19]. The international comparison
of perinatal mortality is complicated by the variability in
the scope and quality of death data between countries.
This includes differing registration criteria and denomin-
ator populations and variability in data collection prac-
tices. The higher PMR for Australia and New Zealand
compared to Sweden and Finland [27,38] is likely related
to the earlier adoption and higher proportions of SET in
Sweden and Finland compared to Australia and New
Zealand. In contrast, the lower PMR for Australia and
New Zealand when compared to Canada, the United
Kingdom and Latin America likely reflects the higher
proportion of SET in Australia and New Zealand than
those countries and regions [3,4,31]. Additionally, stud-
ies have reported better perinatal outcomes of singletons
following SET when compared to singletons following
DET [39,40]. It has also been suggested that twins fol-
lowing SET (considering monozygotic twins) had a
higher risk of perinatal death than twins following DET
(considering dizygotic twins) [41,42]. Therefore, stratifi-
cation by number of embryos transferred and plurality
would allow making direct assessment of the risk of
perinatal mortality due to DET compared to SET, multi-
ples compared to singletons and presumptive monozy-
gotic twins compared to dizygotic twins.
This study used five years of national level Australian
and New Zealand data with approximately 10,000 birthsper year to minimize the effects of random variation and
to maximize the stability and reliability of the mortality
rates. There are some limitations of this study. First,
with all registry studies there is the potential for infor-
mation biases associated with differential ascertainment
of fetal and neonatal deaths from births. However, a re-
cent abstract reported a similar PMR for ART births to
ANZARD using the national perinatal data collection
[43]. Alternatively, if the quality or completeness of peri-
natal mortality data in ART registries is limited, data
linkage among ART, birth and perinatal death registers
is an option. This has the potential to enhance the valid-
ity of the death data internationally as well as providing
information on cause of death [44]. Secondly, we did not
stratify for other patient and treatment related factors
even though published research has shown that ART is
generally associated with more maternal and fetal com-
plications, which vary according to the type of procedure
and type of treatment [45-47]. Instead, we only included
the most critical factors for perinatal mortality, namely
the number of embryos transferred and plurality to
present a public health approach for reporting perinatal
mortality internationally.
Conclusion
International benchmarking of perinatal mortality of ART
births provides essential information to improve the safety
and quality of ART practice. Due to the persisting high rates
of multiple embryo transfers and of multiple birth inter-
nationally best practice is to report all mortality measures by
number of embryo transfers (SET, DET and all transfers)
and plurality (singletons, twins and all). The ICMART /
WHO recommended a perinatal period of ≥ 20 completed
weeks of gestational age to < 7 completed days after birth
which would optimize the standardization of reporting fetal
and neonatal deaths following ART treatment. Noting, this
is currently not possible in Europe and many other coun-
tries. Reporting PMR specifically for three perinatal periods:
≥ 20 weeks gestational age to < 7 days after birth; ≥22 weeks
gestational age to <7 days after birth and ≥ 28 weeks gesta-
tional age to <7 days after birth would allow international
benchmarking of mortality of ART births. This would rap-
idly provide an international evidence-base to evaluate ART
practice and policy against perinatal mortality.
Abbreviations
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(ANZARD); ART: Assisted reproductive technology; DET: Double embryo
transfer; PMR: Perinatal mortality rate; SET: Single embryo transfer.
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